All of the following are second generation antipsychotics except

A. Haloperidol (Haldol) is a first-generation (typical) antipsychotic that primarily blocks dopamine (D2) receptors. It is associated with a higher risk of extrapyramidal side effects (EPS), including dystonia, akathisia, and tardive dyskinesia, compared to second-generation antipsychotics. B. Ziprasidone (Geodon) is a second-generation (atypical) antipsychotic that blocks both dopamine (D2) and serotonin (5-HT2A) receptors. It has a lower risk of EPS but can cause QT prolongation, requiring ECG monitoring in patients with cardiac conditions. C. Risperidone (Risperdal) is a second-generation antipsychotic with dopamine and serotonin antagonism. It is effective for schizophrenia, bipolar disorder, and irritability in autism but has a higher likelihood of prolactin elevation and EPS at higher doses. D. Olanzapine (Zyprexa) is a second-generation antipsychotic known for its high risk of metabolic side effects, including weight gain, diabetes, and dyslipidemia. It has a lower risk of EPS compared to first-generation antipsychotics.